Latest Pharma and Biotech News
Biotechnology
27 March 2025 Johnson & Johnson has announced important overall survival (OS) results from the Phase III MARIPOSA study.
Today's issue
Refine Search
Biotechnology
US gene therapy company bluebird bio has confirmed receipt of an unsolicited non-binding written proposal from Ayrmid Pharma to acquire the company for up to $110.5 million 29 March 2025
Pharmaceutical
The European Medicines Agency’s (EMA’) human medicines committee (CHMP) has recommended two new medicines and three biosimilars for approval at its March 2025 meeting. 28 March 2025
Pharmaceutical
Cardiovascular-focused Milestone Pharmaceuticals was trading more than 60% lower early in trading on Friday, with its share price worth less than $0.90. 28 March 2025
Pharmaceutical
Danish pharma major Novo Nordisk has taken another step in its strategy to maintain dominance in the obesity space by adding complementary mechanisms to pair with its blockbuster bGLP-1 franchise. 28 March 2025
Biotechnology
Japan’s Ministry of Health, Labor and Welfare in Japan has granted marketing and manufacturing authorization for Dupixent (dupilumab) to treat chronic obstructive pulmonary disease (COPD) in adults whose disease is not adequately controlled with existing therapy. 28 March 2025
Pharmaceutical
German life sciences and pharma company Merck KGaA today revealed it has exercised its option with China’s Abbisko Therapeutics for commercialization of pimicotinib in the US and rest of world. 28 March 2025
Pharmaceutical
Singaporean biotech Shanton Pharma has reported positive top-line results from a Phase IIb clinical trial of its investigational gout therapy SAP-001 in patients with refractory disease, a group that often fails to respond to existing oral treatments. 28 March 2025
Biotechnology
US genomics firm Galatea Bio has raised $25 million in funding to expand its global biobank and accelerate the development of AI-powered tools for drug discovery and disease risk prediction, with a particular focus on populations historically left out of genomic research. 28 March 2025
Biotechnology
The interleukin-2 (IL-2) therapies market in the USA is poised for major growth, projected to reach $4 billion by 2034, according to research from DelveInsight. 28 March 2025
Pharmaceutical
Italian biopharma Chiesi Group has announced a major investment in Nerviano, near Milan, with the building of a new facility for the production of its therapeutic solutions. 28 March 2025
Biotechnology
Germany-headquartered CureVac late Thursday announced that the European Patent Office (EPO) has confirmed the validity of CureVac's European patent EP 3 708 668 B1 subject to amendments to specify the scope of protection. 28 March 2025
Biotechnology
US pharma major Merck & Co has shared the first results from a late-stage trial of a subcutaneous version of its blockbuster immunotherapy Keytruda (pembrolizumab), with data presented Thursday at the European Lung Cancer Congress. 28 March 2025
Biotechnology
US clinical stage biopharma Candel Therapeutics has announced final survival data from a Phase IIa clinical trial of CAN-2409 in patients with stage III/IV NSCLC, inadequately responding to ICI treatment. 28 March 2025
Pharmaceutical
German drugmaker Bayer has signed a global licensing agreement with China-based Puhe BioPharma, gaining exclusive rights to develop and commercialize an early-stage precision oncology therapy targeting MTAP-deleted tumors. 27 March 2025
Biotechnology
French biotech company Transgene has reported its 2024 financial results and provided updates on its cancer immunotherapy pipeline. 27 March 2025
Biotechnology
Danish cancer specialist Genmab today announced that the Japanese Ministry of Health, Labor and Welfare has approved Tivdak (tisotumab vedotin) for the treatment of advanced or recurrent cervical cancer that has progressed on or after cancer chemotherapy. 27 March 2025
Biotechnology
Cambridge, USA-based RNS specialist Wave Life Sciences has announced positive data from the Phase II FORWARD-53 trial of WVE-N531, which is an exon skipping oligonucleotide being investigated in boys with Duchenne muscular dystrophy (DMD) who are amenable to exon 53 skipping. 27 March 2025
Pharmaceutical
There has been talk of the job cuts impacting US health agencies for weeks. 27 March 2025
Pharmaceutical
Genetic diseases company BridgeBio Pharma has announced that the Japanese Ministry of Health, Labor and Welfare has approved acoramidis, under the brand name Beyonttra, for the treatment of adults with transthyretin-mediated amyloid cardiomyopathy (ATTR-CM). 27 March 2025
Pharmaceutical
UK-based specialty pharma Kelso Pharma, which is backed by private equity investor Apposite Capital, announced that it has secured over £140 million ($180 million) of acquisition funding. 27 March 2025
All news
Biotechnology
US gene therapy company bluebird bio has confirmed receipt of an unsolicited non-binding written proposal from Ayrmid Pharma to acquire the company for up to $110.5 million 29 March 2025
Pharmaceutical
The European Medicines Agency’s (EMA’) human medicines committee (CHMP) has recommended two new medicines and three biosimilars for approval at its March 2025 meeting. 28 March 2025
Pharmaceutical
Cardiovascular-focused Milestone Pharmaceuticals was trading more than 60% lower early in trading on Friday, with its share price worth less than $0.90. 28 March 2025
Pharmaceutical
Danish pharma major Novo Nordisk has taken another step in its strategy to maintain dominance in the obesity space by adding complementary mechanisms to pair with its blockbuster bGLP-1 franchise. 28 March 2025
Biotechnology
Japan’s Ministry of Health, Labor and Welfare in Japan has granted marketing and manufacturing authorization for Dupixent (dupilumab) to treat chronic obstructive pulmonary disease (COPD) in adults whose disease is not adequately controlled with existing therapy. 28 March 2025
Pharmaceutical
German life sciences and pharma company Merck KGaA today revealed it has exercised its option with China’s Abbisko Therapeutics for commercialization of pimicotinib in the US and rest of world. 28 March 2025
Pharmaceutical
Singaporean biotech Shanton Pharma has reported positive top-line results from a Phase IIb clinical trial of its investigational gout therapy SAP-001 in patients with refractory disease, a group that often fails to respond to existing oral treatments. 28 March 2025
Biotechnology
US genomics firm Galatea Bio has raised $25 million in funding to expand its global biobank and accelerate the development of AI-powered tools for drug discovery and disease risk prediction, with a particular focus on populations historically left out of genomic research. 28 March 2025
Biotechnology
The interleukin-2 (IL-2) therapies market in the USA is poised for major growth, projected to reach $4 billion by 2034, according to research from DelveInsight. 28 March 2025
Pharmaceutical
Italian biopharma Chiesi Group has announced a major investment in Nerviano, near Milan, with the building of a new facility for the production of its therapeutic solutions. 28 March 2025
Biotechnology
Germany-headquartered CureVac late Thursday announced that the European Patent Office (EPO) has confirmed the validity of CureVac's European patent EP 3 708 668 B1 subject to amendments to specify the scope of protection. 28 March 2025
Biotechnology
US pharma major Merck & Co has shared the first results from a late-stage trial of a subcutaneous version of its blockbuster immunotherapy Keytruda (pembrolizumab), with data presented Thursday at the European Lung Cancer Congress. 28 March 2025
Biotechnology
US clinical stage biopharma Candel Therapeutics has announced final survival data from a Phase IIa clinical trial of CAN-2409 in patients with stage III/IV NSCLC, inadequately responding to ICI treatment. 28 March 2025
Pharmaceutical
German drugmaker Bayer has signed a global licensing agreement with China-based Puhe BioPharma, gaining exclusive rights to develop and commercialize an early-stage precision oncology therapy targeting MTAP-deleted tumors. 27 March 2025
Biotechnology
French biotech company Transgene has reported its 2024 financial results and provided updates on its cancer immunotherapy pipeline. 27 March 2025
Biotechnology
Danish cancer specialist Genmab today announced that the Japanese Ministry of Health, Labor and Welfare has approved Tivdak (tisotumab vedotin) for the treatment of advanced or recurrent cervical cancer that has progressed on or after cancer chemotherapy. 27 March 2025
Biotechnology
Cambridge, USA-based RNS specialist Wave Life Sciences has announced positive data from the Phase II FORWARD-53 trial of WVE-N531, which is an exon skipping oligonucleotide being investigated in boys with Duchenne muscular dystrophy (DMD) who are amenable to exon 53 skipping. 27 March 2025
Pharmaceutical
There has been talk of the job cuts impacting US health agencies for weeks. 27 March 2025
Pharmaceutical
Genetic diseases company BridgeBio Pharma has announced that the Japanese Ministry of Health, Labor and Welfare has approved acoramidis, under the brand name Beyonttra, for the treatment of adults with transthyretin-mediated amyloid cardiomyopathy (ATTR-CM). 27 March 2025
Pharmaceutical
UK-based specialty pharma Kelso Pharma, which is backed by private equity investor Apposite Capital, announced that it has secured over £140 million ($180 million) of acquisition funding. 27 March 2025
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze